Brief: Zynerba Pharma Says New Data Describes Statistically Significant Results From Phase 2 Bright Trial

Zynerba Pharmaceuticals

15/10/2020 20:21

Oct 15 (Reuters) - Zynerba Pharmaceuticals Inc  ZYNE.O :
    * NEW DATA DESCRIBING STATISTICALLY SIGNIFICANT RESULTS FROM
THE
PHASE 2 BRIGHT TRIAL IN PATIENTS WITH AUTISM SPECTRUM DISORDER
(ASD) PRESENTED AT THE VIRTUAL JOINT 16TH INTERNATIONAL CHILD
NEUROLOGY CONGRESS (ICNC) & 49TH ANNUAL CHILD NEUROLOGY SOCIETY
(CN
    * ZYNERBA PHARMA-PATIENTS RECEIVING ZYGEL IN STUDY ACHIEVED
STATISTICALLY SIGNIFICANT CAREGIVER-REPORTED IMPROVEMENTS VERSUS
BASELINE ACROSS SUBSCALES OF AIM

Source text for Eikon:  ID:nGNX8Fxr0k 
Further company coverage:  ZYNE.O 

 ((Reuters.Briefs@thomsonreuters.com;))